LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, has been selected to receive a highly competitive Women TechEU grant. Women TechEU is a project funded through Horizon Europe, the EU's flagship research and innovation funding program.
The award, one of only 40 out of over a 1,000 applications from across 38 eligible countries, recognises LinkGevity's groundbreaking work in tackling complex, age-related diseases through an innovative approach to drug discovery. The company leverages its proprietary Blueprint Theory of Aging, which identifies critical pathological pathways shared across multiple diseases and conditions. This breakthrough allows us to move beyond traditional single-disease therapies, enabling the development of broad-spectrum therapeutics that target the root causes of multiple age-related conditions simultaneously.
Using this innovative approach, the company has already discovered a promising "Anti-Necrotic" therapeutic, which targets a key biological pathway linked to six of the top ten global causes of death. This same pathway has for years been a stumbling block in organ preservation, cryopreservation, and bio-engineering. LinkGevity has recently been recognised by NASA's Space-H program for its work which could help support deep-space missions and protect astronaut health (press release here).
"Our AI-driven platform identifies shared molecular pathways across diseases, offering the potential to treat complex multifaceted conditions more effectively," said Dr. Carina Kern, CEO and co-founder of LinkGevity. "This isn't just about discovering one drug for one disease - we're uncovering entire classes of therapeutics with applications across multiple diseases. And because the pathways we uncover are so fundamental in biological collapse, our therapeutics have wider ...
